Springer Nature
Browse
13063_2018_2613_MOESM1_ESM.doc (122.5 kB)

Additional file 1: of Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

Download (122.5 kB)
journal contribution
posted on 2018-04-12, 05:00 authored by Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, Dewi Vernerey, Thierry Nguyen Tan Hon, Hamadi Almotlak, Ulrich Stein, Fabien Calcagno, Diane Berthod, Elise Robert, Aurelia Meurisse, Antoine Thiery-Vuillemin
SPIRIT checklist. (DOC 122 kb)

Funding

Pfizer

History

Usage metrics

    Trials

    Categories

    Keywords

    Renal cell carcinomaSunitinibMetastaticScheduleToxicitySafetyHealth-related quality of life

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC